Synteract’s Continued Growth as a Leading CRO Results in Plans to Open Additional Office in Swansea, Wales
A full list of open positions for the company globally can be found on the Synteract Careers site.
Representatives from Synteract,
an innovative CRO partnering with biotech and pharma companies to bring
new medicines to market, will visit Swansea,
Wales, from March 21-23 to conduct interviews for an expansion
office focused on technical expertise, proposals, and financial project
management. The contract research organization is responding to
sustained growth of its business by ramping up recruitment now with
plans to open the office in late second quarter of 2019.
The second-largest city in Wales, Swansea has been chosen for
Synteract’s next office location due to its proximity to multiple
universities that provide access to a rich pool of skilled workers, and
its history as a good location for contract research organizations.
Specific job titles being sought currently in Swansea include the
following:
- Clinical Data Coordinator
- Statistical Programmer
- Senior Stats Programmer
- Biostatistician
- Senior Biostatistician
- Process Analyst
Near term position possibilities also include Safety Surveillance
Associate, Clinical Data Manager, and Document Quality Review
Specialist. A full list of open positions for the company globally can
be found on the Synteract
Careers site.
Synteract is a growth-oriented CRO with multiple international offices,
managing complex, global clinical trials in specialized therapeutic
areas. It is an equal opportunity employer with competitive benefits and
salaries, a collaborative team environment, and offers professional and
personal growth opportunities for employees.
Talented individuals interested in interviewing can schedule an
appointment with Synteract representatives by contacting Cassie Hauser, [email protected].
About Synteract
“Bringing Clinical Trials to Life” represents Synteract’s commitment to
engage with drug developers, patients, investigators, and regulatory
experts, to bring insights to action and make better therapies a
reality. With 800 employees across 21 countries, Synteract
supports biotech and pharma companies across all phases of drug
development to help bring new medicines to market. Synteract has
conducted nearly 4,000 studies on six continents and in more than 60
countries. It has contributed to more than 240 product approvals.
Synteract offers a notable depth of therapeutic expertise in oncology,
dermatology, neuro degenerative, pediatrics, and rare and orphan
diseases. Connect on LinkedIn
and Twitter.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190320005165/en/